Matti Annala

16.7k total citations · 1 hit paper
86 papers, 3.4k citations indexed

About

Matti Annala is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research and Molecular Biology. According to data from OpenAlex, Matti Annala has authored 86 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 61 papers in Pulmonary and Respiratory Medicine, 60 papers in Cancer Research and 33 papers in Molecular Biology. Recurrent topics in Matti Annala's work include Prostate Cancer Treatment and Research (49 papers), Cancer Genomics and Diagnostics (43 papers) and Prostate Cancer Diagnosis and Treatment (11 papers). Matti Annala is often cited by papers focused on Prostate Cancer Treatment and Research (49 papers), Cancer Genomics and Diagnostics (43 papers) and Prostate Cancer Diagnosis and Treatment (11 papers). Matti Annala collaborates with scholars based in Finland, Canada and United States. Matti Annala's co-authors include Matti Nykter, Alexander W. Wyatt, Kim N., Kevin Beja, Martin Gleave, Gillian Vandekerkhove, Evan W. Warner, Daniel Khalaf, Arun Azad and Bernhard J. Eigl and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Matti Annala

79 papers receiving 3.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer

2018 347 citations Matti Annala, Gillian Vandekerkhove et al. Cancer Discovery profile →

Peers

Matti Annala

PRM

ONCOL

SURGE

Michael T. Schweizer United States

Amado J. Zurita United States

Anand Mayakonda United States

Virote Sriuranpong Thailand

Manav Korpal United States

Ryon P. Graf United States

Irina A. Lubensky United States

Tobias Zellweger Switzerland

Lara Felicioni Italy

Genichiro Ishii Japan

Michael T. Schweizer United States

Matti Annala

2.2k ×1.1

PRM

746 ×0.5

929 ×0.6

1.1k ×1.3

ONCOL

321 ×0.9

SURGE

Citations per year, relative to Matti Annala Matti Annala (= 1×) peers Michael T. Schweizer

Countries citing papers authored by Matti Annala

Since Specialization

Citations

This map shows the geographic impact of Matti Annala's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matti Annala with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matti Annala more than expected).

Fields of papers citing papers by Matti Annala

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matti Annala. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matti Annala. The network helps show where Matti Annala may publish in the future.

Co-authorship network of co-authors of Matti Annala

This figure shows the co-authorship network connecting the top 25 collaborators of Matti Annala. A scholar is included among the top collaborators of Matti Annala based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matti Annala. Matti Annala is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Micarelli, Elisa, Lauri Moilanen, Matti Annala, et al.. (2025). NOUS-209 Off-the-shelf Immunotherapy Has the Potential to Hit Primary and Metachronous Colorectal and Urothelial Cancers in Lynch Syndrome. Molecular Cancer Therapeutics. OF1–OF12.

Moilanen, Lauri, Maarit Ahtiainen, Kirsi Pylvänäinen, et al.. (2025). Constrained hypermutation and absence of TERT promoter mutations in Lynch syndrome-associated urothelial cancer. Cell Reports. 44(10). 116388–116388.

Sumiyoshi, Takayuki, Xiaofei Wang, Evan W. Warner, et al.. (2023). Molecular features of prostate cancer after neoadjuvant therapy in the phase 3 CALGB 90203 trial. JNCI Journal of the National Cancer Institute. 116(1). 115–126. 2 indexed citations

Tolmeijer, Sofie H., Takayuki Sumiyoshi, Edmond M. Kwan, et al.. (2023). Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research. 29(15). 2835–2844. 26 indexed citations

Schönlau, Elena, David C. Müller, Gillian Vandekerkhove, et al.. (2023). Evaluating the use of circulating tumor DNA (ctDNA) in patients with urothelial cancer in the context of FGFR-targeted therapy.. Journal of Clinical Oncology. 41(16_suppl). 4577–4577.

Annala, Matti, Sinja Taavitsainen, Daniel Khalaf, et al.. (2021). Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition. Clinical Cancer Research. 27(16). 4610–4623. 52 indexed citations

Warner, Evan W., Cameron Herberts, Simon Fu, et al.. (2021). BRCA2 , ATM , and CDK12 Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical Aggression. Clinical Cancer Research. 27(6). 1650–1662. 52 indexed citations

Vandekerkhove, Gillian, Jean‐Michel Lavoie, Matti Annala, et al.. (2021). Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer. Nature Communications. 12(1). 184–184. 109 indexed citations

Shcherban, Anastasia, Matti Annala, Alfonso Urbanucci, et al.. (2020). AR and ERG drive the expression of prostate cancer specific long noncoding RNAs. Oncogene. 39(30). 5241–5251. 9 indexed citations

10.

Annala, Matti, Gillian Vandekerkhove, Daniel Khalaf, et al.. (2018). Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer. Cancer Discovery. 8(4). 444–457. 347 indexed citations breakdown →

11.

Kallio, Heini, Reija Hieta, Leena Latonen, et al.. (2018). Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases. British Journal of Cancer. 119(3). 347–356. 66 indexed citations

12.

Annala, Matti, Sinja Taavitsainen, Gillian Vandekerkhove, et al.. (2018). Frequent mutation of the FOXA1 untranslated region in prostate cancer. Communications Biology. 1(1). 122–122. 18 indexed citations

13.

Beltran, Himisha, Alexander W. Wyatt, Edmund C.P. Chedgy, et al.. (2017). Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy. Clinical Cancer Research. 23(22). 6802–6811. 52 indexed citations

14.

Kivinummi, Kati, Alfonso Urbanucci, Katri A. Leinonen, et al.. (2017). The expression of AURKA is androgen regulated in castration-resistant prostate cancer. Scientific Reports. 7(1). 17978–17978. 41 indexed citations

15.

Vandekerkhove, Gillian, Tilman Todenhöfer, Matti Annala, et al.. (2017). Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer. Clinical Cancer Research. 23(21). 6487–6497. 122 indexed citations

16.

Kesseli, Juha, Matti Annala, Kristiina Nordfors, et al.. (2017). Clinical association analysis of ependymomas and pilocytic astrocytomas reveals elevated FGFR3 and FGFR1 expression in aggressive ependymomas. BMC Cancer. 17(1). 310–310. 20 indexed citations

17.

Saramäki, Outi R., Matti Annala, Katri A. Leinonen, et al.. (2016). 1074 Microseminoprotein-beta expression in different stages of prostate cancer. European Urology Supplements. 15(3). e1074–e1074. 2 indexed citations

18.

Ylipää, Antti, Kati Kivinummi, Matti Annala, et al.. (2015). Transcriptome Sequencing Reveals PCAT5 as a Novel ERG-Regulated Long Noncoding RNA in Prostate Cancer. Cancer Research. 75(19). 4026–4031. 58 indexed citations

19.

Chedgy, Edmund C.P., Matti Annala, Kevin Beja, et al.. (2015). Moving Toward Personalized Care: Liquid Biopsy Predicts Response to Cisplatin in an Unusual Case of BRCA2-Null Neuroendocrine Prostate Cancer. Clinical Genitourinary Cancer. 14(2). e233–e236. 15 indexed citations

20.

Yang, Jilong, Matti Annala, Ping Ji, et al.. (2014). Recurrent LRP1-SNRNP25 and KCNMB4-CCND3 fusion genes promote tumor cell motility in human osteosarcoma. Journal of Hematology & Oncology. 7(1). 76–76. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact